Half yearly performance report - January to June 2015

16 December 2015

The half yearly performance report

This half yearly performance report covers the period 1 January to 30 June 2015 inclusive.

Future reports will be published annually, with the next report covering July 2015 to June 2016. This is in line with the report against the TGA key performance indicators and measures: Regulator Performance Framework.

The KPI report outlines performance against our broad strategic intent, and should be read in conjunction with the performance statistics provided in the future copies of this report.

About the TGA

The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health, and is responsible for ensuring that therapeutic goods available for supply in or exported from Australia are safe and fit for their intended purpose. We regulate the import, supply, export, manufacture and advertising of therapeutic goods including:

  • medicines: prescription and over-the-counter medicines, vaccines, complementary medicines, and blood and plasma products
  • medical devices: which includes a wide variety of products ranging from lower risk items like adhesive bandages through to higher risk devices like pacemakers
  • biologicals: stem cells, tissues and cell based products.

For more information about the type of products we regulate, and how the regulatory system works, please visit the TGA basics section of our website.

Version history

Version Description of change Author Effective date
V1.0 Original publication Reporting and Collaborative Services December 2015

1. Prescription medicines

Applications to register new, or vary existing, prescription medicines are accompanied by supportive scientific data and evaluated appropriately; with timeframes underpinned by legislation and/or associated business rules.

The framework for prescription medicines includes the following categories which are subject to legislated timeframes:

  • Category 1 application: An application to register a new prescription medicine (other than an additional trade name) or to make a variation to an existing medicine that involves the evaluation of clinical, pre-clinical or bio-equivalence data.
  • Examples of Category 1 applications include new chemical entities, extensions of indication, and new routes of administration. The legislated timeframes for the two stages of a Category 1 application are: 40 working days for notification of acceptance or rejection of the application and 255 working days for the completion of the evaluation and notification of the decision.
  • Category 2 application: Differs from a Category 1 application in that it is accompanied by two independent evaluation reports from comparable overseas regulators in whose jurisdiction the product is approved for the same indication.
  • The legislated timeframes for the two stages of a Category 2 application are: 20 working days for notification of acceptance or rejection of an application and 175 working days to notify the applicant of the decision.
  • Category 3 application: An application to register or to vary the registration of a prescription medicine where the application does not require the support of clinical, pre-clinical or bio-equivalence data.
  • Examples of Category 3 applications include a change in the site of manufacture, a change to the synthetic route, a change in the product specifications, a change in the steps of manufacture or a change in trade name.
  • The legislated timeframe for a Category 3 application is 45 working days for notification of acceptance or rejection of an application, completion of evaluation and notification of the decision.

1.1 Approval times

Once an application has been accepted by the TGA, the approval time is defined as the number of TGA working days until a decision is made. As detailed above, this timeframe is underpinned by legislation and excludes public holidays, weekends, the time allocated to the applicant to provide responses to requests for information and 'mutual clock stop' periods agreed with the applicant.

In accordance with the Therapeutic Goods Regulations 1990, a 'submission' may include a number of applications submitted at the one time. The data presented below relates to submissions as this best reflects the evaluation and decision-making processes.

Table 1: Prescription medicine approval times for January to June 2015
Approval time
Application type Legislated timeframe Mean Median Minimum Maximum
A: New chemical entity
Category 1 255 200 206 88 251
B: New fixed-dose combination
Category 1 255 183 189 133 239
C: Extension of indication
Category 1 255 192 206 40 240
D: New generic medicine
Category 1 255 177 169 127 253
E: Additional trade name
Category 1 255a 190 196 111 285
F: Major variationb
Category 1 255 188 189 126 244
G: Minor variationc
Category 1 255 0 0 0 0
Category 3 45 17 17 6 37
H: Minor variationd
Category 1 255 131 101 56 237
Category 3 45 22 18 1 106
J: Changes to product information requiring the evaluation of data
Category 1 255 152 162 18 245
  1. In July 2015, a new process with a new legislative timeframe was introduced for additional trade name submissions. During the reporting period relevant to this report, these applications were under the Category 1 framework and a legislated timeframe of 255 working days applied.
  2. During this reporting period, the TGA also approved one Category 2 application (F: Major variation) in 151 working days.
  3. The type G minor variations differ from type H minor variations in that they result in a new ARTG entry.
  4. The minor variations (type H) included in the table above refer to applications to change the formulation, composition or design specification or the container for the goods or any other attribute that results in the goods being separate and distinct. These applications are typically 'Category 3' changes, unless the supporting scientific package contains non-clinical or clinical data in which case the application is a 'Category 1' application.

1.2 Submission outcomes

Table 2: Number of completed prescription medicine submissions by type and outcome for January to June 2015
Submission Type Approved Withdrawn Rejected Total
A: New chemical entity 16 1 1 18
B: New fixed-dose combination 7 0 0 7
C: Extension of indication 21 0 0 21
D: New generic medicine 56 6 0 62
E: Additional trade name 15 1 0 16
F: Major variation 21 2 0 23
G: Minor variation 70 0 0 70
H: Minor variation (Category 1) 3 0 0 3
H: Minor variation (Category 3) 652 3 1 656
J: Changes to Product Information 39 4 0 43
Total 900 17 2 919

1.3 Other applications

In addition to the application types discussed above, the TGA also processes numerous other application types. These applications are assessed in accordance with a risk-based approach, for example, some requests are categorised as 'self-assessable' and do not usually involve the evaluation of scientific data. Some applications are received because the sponsors are obliged to inform the TGA of new information related to the safety of their products. Other applications involve editorial corrections to the register entry or the associated product information document. The number of such applications is presented below.

In accordance with the legislation, registered goods must comply with numerous standards at the time they are registered and throughout their lifecycle. Following an appropriate application and review of the scientific data and safety considerations, the TGA may grant an 'exemption' from a particular standard for a product. The number of such applications approved and rejected is also included in the following table.

Table 3: Number of other Prescription Medicine applications
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Safety related request 358 360 390
Self-assessable request 582 608 621
Minor editorial change to product information 264 272 281
Correction of error 98 94 69
Total 1302 1334 1361
Exemptions to comply with a standard
Approved N/Aa N/Aa 34
Rejected N/Aa N/Aa 0
Total N/Aa N/Aa 34
  1. N/A - This data is not available as it was not being collected for these periods.

1.4 Orphan drug designations

'Orphan drugs' are often developed to treat small and very specific patient populations who suffer from rare diseases and conditions. The application and evaluation fees for orphan drugs can be waived to help reduce their development costs and facilitate their access to the Australian marketplace. A medicine needs to be designated by the TGA as an orphan drug before an application can be accepted to register it on the Australian Register of Therapeutic Goods (ARTG). The designation process involves a review of whether the drug meets the established criteria which are underpinned by legislation. The quality, efficacy and safety of orphan drugs are assessed at the same standard as for other registered prescription medicines.

Table 4: Number of orphan drug designations
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Number of designations 11 11 9

2. Over-the-Counter medicines

Over-the-Counter (OTC) medicines applications are categorised as new medicine (N) or change (C) applications and are further categorised by risk (N1 and C1 are low risk, N5 and C4 are highest risk). The OTC application categorisation framework outlined below defines the different OTC medicine application levels and the key application criteria.

Table 5: Categorisation of OTC medicines applications
Application category Definition
N1 An application submitted as a 'Clone'.
N2 An application which complies with an over-the-counter medicine monograph.
N3 New application for a 'generic' medicine other than those 'generic' applications in levels N1, N2 or N4.
N4

An application for a 'generic' medicine where the medicine:

is included in Appendix X (but which is not a level N1 application) and/or

includes an umbrella branded product name where the umbrella segment is categorised as requiring a higher level of assessment and/or

requires supporting safety and/or efficacy (clinical/toxicological) data or a justification for not providing such data.

N5 An application for a new product that is an extension to a 'generic category' product or an application for a product containing a new chemical entity as an active ingredient.
C1 Quality and non-quality changes.
C2 Quality changes or non-quality changes - no safety and efficacy data required.
C3 Umbrella branding - higher level of assessment or non-quality changes - safety and efficacy data may be required.
C4 Non-quality changes - data are required.

2.1 Approval times

Approval time is defined as the number of working days from the acceptance of the application until formal notification of decision. Approval time excludes time where the TGA was unable to progress the application until the sponsor provided additional information unless otherwise specified.

We aim to have 80% of applications completed within target timeframes. Target timeframes for processing of applications are a result of new OTC pre-market business processes and are subject to ongoing review.

Table 6: Mean approval time for OTC medicine applications
2014 2015
Jan-Jun Jul-Dec Jan-Jun

New medicine applications

N1 21 30 23
N2 49 29 31
N3 97 51 66
N4 105 125 64
N5 N/Aa 123 75

Change applications

C1 16 8 12
C2 40 16 19
C3 33 84 47
C4 69 0 44
  1. The one N5 application processed to a decision in January to June 2014 was submitted prior to implementation of the new business process.
Table 7: OTC medicine approval time against target time by application category for January to June 2015
Application type Number completed Range Mean Median Target time % within target
New medicines
N1 56 6-44 23 21 45 100
N2 1 N/A 31 31 75 100
N3 8 19-121 66 52 150 100
N4 10 29-106 64 59 170 100
N5 3 70-80 75 74 210 100
Change applications
C1 265 2-41 12 11 20 91
C2 126 0-64 19 11 64 100
C3 2 15-79 47 47 120 100
C4 5 44 44 44 170 100
Total 476
Table 8: Percentage of OTC medicine applications processed within target time
2014 2015
Jan-Jun Jul-Dec Jan-Jun
New medicine applications (%)
N1 98 94 100
N2 100 100 100
N3 100 100 100
N4 100 100 100
N5 N/Aa 100 100
Change applications (%)
C1 84 96 91
C2 98 99 100
C3 100 67 100
C4 100 N/Ab 100
  1. The one N5 application processed to a decision in January to June 2014 was submitted prior to implementation of the new business process.
  2. There were no C4 applications finalised in this period.

2.2 Applications

2.2.1 New OTC medicine applications

Table 9: Applications received for new OTC medicines and changes to existing medicines
2014 2015
Jan-Jun Jul-Dec Jan-Jun
New medicine applications
N1 138 88 56
N2 0 8 1
N3 18 21 28
N4 13 45 13
N5 5 8 6
Total 174 170 104
Change applications
C1 183 255 290
C2 129 125 136
C3 8 2 2
C4 0 11 6
Total 320 393 434

2.2.2 Completed applications

Table 10: New OTC medicine applications completed and outcomes
2014 2015
Jan-Jun Jul-Dec Jan-Jun
N1
Approved 131 106 56
Rejected 0 0 0
Withdrawn by sponsor 5 9 0
Returned/failed screening 0 1 0
Total 136 116 56
N2
Approved 2 8 1
Rejected 0 0 0
Withdrawn by sponsor 0 0 0
Returned/failed screening 0 0 0
Total 2 8 1
N3
Approved 38 19 8
Rejected 0 0 0
Withdrawn by sponsor 1 0 1
Returned/failed screening 2 2 7
Total 41 21 16
N4
Approved 17 46 10
Rejected 1 0 0
Withdrawn by sponsor 0 5 1
Returned/failed screening 6 7 4
Total 24 58 15
N5
Approved 1 12 3
Rejected 0 0 0
Withdrawn by sponsor 2 0 0
Returned/failed screening 2 5 4
Total 5 17 7
Table 11: OTC change applications completed and outcomes
2014 2015
Jan-Jun Jul-Dec Jan-Jun
C1
Approved 184 257 265
Rejected 0 0 0
Withdrawn by sponsor 7 4 3
Returned/failed screening 0 0 0
Total 191 261 268
C2
Approved 169 129 126
Rejected 0 0 0
Withdrawn by sponsor 1 4 6
Returned/failed screening 0 1 4
Total 170 134 136
C3
Approved 6 3 2
Rejected 0 0 0
Withdrawn by sponsor 0 0 0
Returned/failed screening 0 0 0
Total 6 3 2
C4
Approved 3 0 5
Rejected 0 0 0
Withdrawn by sponsor 0 0 0
Returned/failed screening 0 0 0
Total 3 0 5

3. Complementary medicines

3.1 Registered complementary medicines

Registered complementary medicines are considered to be of relatively higher risk than listed medicines based on their ingredients or the indications for the medicine. These medicines are fully evaluated by the TGA for quality, safety and efficacy prior to being accepted on the Australian Register of Therapeutic Goods (ARTG).

Table 12: Registered complementary medicine applications by outcome
2014 2015
Jan-Jun Jul-Dec Jan-Jun
New medicines
Approved 0 3 1
Rejected 0 1 0
Withdrawn 0 0 0
Returned/failed screening 0 0 0
Total new applications completed 0 4 1
Variations
Approved 5 15 13
Rejected 0 1 0
Withdrawn 0 0 1
Returned/failed screening 0 0 0
Total variations completed 5 16 14
Application for consent to import, supply or export goods under section 14/14A of the Acta
Approved N/Ab N/Ab 0
Rejected N/Ab N/Ab 0
Total applications a completed N/Ab N/Ab 0
  1. Applications can be made for consent to import, supply or export goods under section 14/14A of the Therapeutic Goods Act 1989.
  2. N/A - This data is not available as it was not being collected for these periods.

3.2 New ingredients permitted for use in listed medicines

Table 13: New listed medicine ingredient applications by outcome
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Approved 2 4 1
Rejected 4 0 1
Withdrawn 0 0 0
Returned/failed screening 0 0 0
Total completed 6 4 2

3.3 Listed medicines

Table 14: New listed medicines
2014 2015
Jan-Jun Jul-Dec Jan-Jun
New listed medicines 970 1 022 857
Table 15: Listed medicine variations under section 9D of the Therapeutic Goods Act 1989
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Approved N/Aa N/Aa 56
Rejected N/Aa N/Aa 3
Total N/Aa N/Aa 59
  1. N/A - This data is not available as it was not being collected for these periods.

Section 9D of the Therapeutic Goods Act 1989 provides for variations to be made to an entry on the ARTG in a set of limited and prescribed circumstances. These circumstances include where information included in the ARTG is incomplete or incorrect.

Table 16: Listed medicine applications under section 14/14A of the Therapeutic Goods Act 1989
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Exemption Granted N/Aa N/Aa 2
Rejected N/Aa N/Aa 1
Total N/Aa N/Aa 3
  1. N/A - This data is not available as it was not being collected for these periods.

Sponsors can apply for certain exemptions under Section 14 of the Therapeutic Goods Act 1989. Applications seeking consent to import, export or supply a complementary medicine that does not comply with the applicable standards.

3.4 Listed medicine reviews

3.4.1 Investigations

Investigations include complaints and referrals from internal and external stakeholders and screening of recently listed medicines on the ARTG, but can also include products not listed on the ARTG. All investigations are assessed and triaged based on a risk management approach to provide the greatest overall benefit for the Australian public. Investigations may be completed through a number of mechanisms, such as initiating a targeted review or referral to another area of the TGA.

Table 17: Listed medicines investigations undertaken and outcomes
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Initiated investigations 49 38 48
Completed investigations
Medicines prioritised for targeted review N/Aa N/Aa 24
Referred to another TGA area or government organisation N/Aa N/Aa 5
No further action taken N/Aa N/Aa 24
Total completed investigations 32 46 53
  1. N/A - This data is not available as it was not being collected for these periods.

The outcome 'no further action taken' includes examples where the investigation was resolved by other means such as the product has been or is currently under review; the complaint was not justified and did not warrant further action; advice was provided to the complainant.

3.4.2 Compliance reviews

Listed medicines are not evaluated by the TGA before they are included on the ARTG. However, a proportion is reviewed to check their compliance against relevant regulatory requirements. Compliance reviews may only review selected listing requirements.

Medicines may be randomly selected or targeted for a review. Medicines are randomly selected for review by a computer, based on a mathematical model. Targeted reviews can originate from a number of signals and are initiated following an investigation.

A compliance review will result in one of the following outcomes:

  • no compliance breaches are identified, the review is concluded and the medicine remains on the ARTG
  • compliance breaches are identified for the selected listing requirements
  • the review is not completed as the sponsor cancelled the medicine or information was not available to conduct the review and the review was closed and the compliance status was unable to be determined.
Table 18: Listed medicine reviews
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Initiated reviews
Targeted reviews 47 21 20
Random reviews 22 13 76
Total 69 34 96
Reviews on hand 178 86 102
Completed reviews
Targeted reviews 68 113 43
Random reviews 21 20 36
Total 89 133 79
Table 19: Outcomes of completed listed medicine reviews
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Compliance status determined
Medicines with no compliance breaches 18 23 20
Medicines with verified compliance breaches 43 80 38
Sub-total 61 103 58
Compliance status unable to be determined
Medicines cancelled by sponsors after request for information 18 18 13
Medicines not yet manufactured 10 12 6
Other 0 0 2
Sub-total 28 30 21
Product not a therapeutic good 0 0 0
Total completed 89 133 79

Figure 1: Outcomes of compliance reviews by reason for initiation

Figure 1 is a pie chart broken down into the percentage of outcomes for compliance reviews by reason for initiation for January to June 2015.

We are currently focussing on performing a higher number of random reviews than in previous periods to better inform our targeted compliance program. In this period, we were able to determine the compliance status of approximately three quarters of reviews we performed, and of these, around 34% were compliant. This is a higher rate of compliance compared to the previous period.

Text version of Figure 1
  • Compliance status determined - 73%
    • No compliance breaches - 34%
      • Target - 50%
      • Random - 50%
  • Compliance status unable to be determined - 27%
    • Medicines cancelled by sponsor after request for information - 62%
      • Target - 77%
      • Random - 23%
    • Medicines not yet manufactured - 29%
      • Random - 67%
      • Target - 33%
    • Other - 9%
      • Random - 100%
    • Verified compliance breaches - 66%
      • Target 55%
      • Random - 45%

Of the completed compliance reviews, the following are the types of issues identified in those medicines where a compliance breach was verified. Individual medicines may have multiple issues.

Table 20: Types of listed medicine compliance issues identified
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Information provided in ARTG entry 4 3 6
Manufacturing, quality and/or formulation 8 6 9
Labelling and/or advertising 49 34 26
Evidence 14 25 17
Safety 0 0 0
Other 6 40 4

Figure 2: Types of compliance issues identified by reason for initiation

Figure 2 are pie charts broken down into random and targetted reviews for January to June 2015.
Figure 2 shows the types of compliance issues that are identified through reviews which are either randomly selected or targeted for a particular issue.

'Other' compliance issues may include the sponsor failing to comply with a condition that the medicine is subject to or not responding to a formal request for information.

For both random and targeted reviews, the most common compliance issues have consistently been labelling/advertising and evidence issues. It is apparent that compliance issues relating to evidence requirements dominate the types of issues identified during random reviews, while labelling/advertising issues are the most common issues identified during targeted reviews. A possible explanation for the higher proportion of labelling/advertising issues for targeted reviews may be that targeted reviews are often informed by complaints or referrals of potential non-compliance issues. As labelling and advertising requirements are easily accessible public information about listed medicines, these issues are often raised with the TGA more frequently and may explain the higher rate.

Text version of Figure 2
  • Random reviews
    • Evidence - 45%
    • Lab elling/advertising - 35%
    • Quality - 17%
    • ARTG information - 3%
  • Targeted reviews
    • Labelling/advertising - 49%
    • ARTG information - 15%
    • Quality - 12%
    • Other - 12%
    • Evidence - 12%
Table 21: Actions taken following listed medicine reviews
Actions following a Request for Information
Medicines found to be compliant and review concluded 20
Medicines cancelled by the TGA without a proposal to cancel notice 1
Proposal to cancel notice sent by the TGA 37
Total 58
Actions following Proposal to Cancel notice
Medicines cancelled by the TGA 6
Medicines cancelled by sponsors after being notified of compliance breaches 10
Reviews concluded after compliance breaches were addressed 21
Sub-total 37
  • The figures provided under 'Actions following Proposal to Cancel notice' are a sub-set of the figure provided under 'Actions following a Request for Information'.

Figure 3: Actions taken following listed medicine reviews categorised by compliance status

Figure 3 is a pie chart broken down into the outcomes of listed medicines reviews for January to June 2015.

Figure 3 shows that a significant proportion of listed medicines reviews are concluded after the Sponsor has adequately addressed the compliance breaches identified by us. Under the Therapeutic Goods Act 1989 sponsors are given an opportunity to respond to issues raised during a compliance review. This high proportion also shows that industry is willing to work with the TGA to ensure the supply of compliant medicines on the ARTG.

Text version of figure 3
  • Non-compliant - 66%
    • Review concluded after compliance breaches addressed - 37%
    • Medicine cancelled by Sponsor after being notified of compliance breaches - 17%
    • Medicine cancelled by TGA after a proposal to cancel notice - 10%
    • Medicine cancelled by TGA without a proposal to cancel notice - 2%
  • Compliant - 34%
    • Medicine found to be compliant and review concluded - 34%

4. Biologicals

The Australian regulatory guidelines for biologicals defines the different Biological classes.

4.1 Inclusion of biologicals

Table 22: Applications for biologicals received and on hand
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Applications received
Technical Master File (TMF) new 0 0 0
TMF annual updates 1 5 3
TMF variations 8 5 2
TMF notifications 4 5 3
Plasma Master File annual updates 12 6 10
Biological Class 2 - new applications 1 1 0
Biological Class 3 - new applications 0 0 0
Biological Class 2 - variations 0 2 3
Biological Class 3 - variations 4 1 1
Total received 30 25 22
Applications on hand
Technical Master File (TMF) new 2 2 1
TMF annual updates 4 4 2
TMF variations 7 0 0
TMF notifications 3 2 0
Plasma Master File annual updates 6 7 8
Biological Class 2 - new applications 20 11 3
Biological Class 3 - new applications 2 2 2
Biological Class 2 - variations 0 1 0
Biological Class 3 - variations 1 1 4
Total on hand 45 30 20
Table 23: Completed applications for Biologicals
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Technical Master File (TMF) new 0 0 1
TMF annual updates 0 2 2
TMF variations 1 6 0
TMF notifications 1 5 0
Plasma Master File annual updates 6 9 8
Biological Class 2 - new applications 0 9 3
Biological Class 3 - new applications 0 4 2
Biological Class 2 - variations 0 1 0
Biological Class 3 - variations 3 0 4
Total completed 11 36 20

5. Medicine and vaccine adverse event reports

5.1 Adverse medicine and vaccine reaction notifications

Table 24: Source of notifications of medicine and vaccine adverse reaction
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Reports with clear causality, by reporter
Hospitals

978

1 205

1 197

Companies

4 183

4 202

4 744

General practitioners

397

340

405

Specialists

93

122

106

Pharmacists

630

594

638

Members of the public (consumers)

298

231

319

Nurses, dentists, complementary healthcare practitioners

117

113

111

State/Territory Health departments

1 636

1 048

1 512

Reports withdrawn, or rejected, or without clear causality
952 797 973
Total received 9 284 8 652 10 005
Mean number of reports received weekly 357 332

385

Vaccine reports included in above table 2 008 1 276

1 983

6. Medical devices

The regulatory framework for medical devices spans the life cycle for these products, including:

  • Conformity assessment: The systematic examination by the manufacturer to determine that a medical device is safe and performs as intended and, therefore, conforms to the Essential Requirements. Certification of the manufacturer's conformity assessment procedure may (and in some cases must) be undertaken by TGA, or the TGA may recognise conformity assessment certification from European notified bodies.
  • Inclusion on the ARTG: Medical devices cannot be imported, supplied in, or exported from Australia unless they are included in the ARTG (unless a valid exemption applies).1 A sponsor can apply to include a medical device in the ARTG if the device complies with the Essential Principles and appropriate conformity assessment procedures have been applied to the device (typically demonstrated through conformity assessment certification).
  • Post-market monitoring: Once a medical device has been included in the ARTG the device must continue to meet all the regulatory, safety and performance requirements and standards that were required for the approval.

6.1 Conformity assessment

6.1.1 Applications

Table 25: Number of conformity assessment applications (medical devices including IVDs)
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Applications received 98 112 81
Applications on hand 162 115 123
Applications completed 131 125 83

6.1.2 Outcomes

Figure 4: Outcomes of conformity assessment applications

The number of applications approved, rejected and withdrawn/lapsed for conformity assessment applications for the periods Jan-Jun 2014; Jul-Dec 2014 and Jan-Jun 2015.

Text version of figure 4
  • Jan-Jun 2014
    • Approved - under 120
    • Rejected - under 140
    • Withdrawn/Lapsed - over 160
  • Jul-Dec 2014
    • Approved - over 80
    • Rejected - over 80
    • Withdrawn/Lapsed - under 120
  • Jan-Jun 2015
    • Approved - over 60
    • Rejected - over 60
    • Withdrawn/Lapsed - over 80

6.1.3 Processing times

The TGA is required to complete conformity assessment applications within 255 working days.

Processing time is defined as the number of working days from the acceptance of the application until formal notification of decision. Under the Therapeutic Goods Regulations 1990, working days exclude public holidays and weekends. Processing time excludes time where the TGA was unable to progress the application until the sponsor provided additional information unless otherwise specified.

Table 26: Percentage of applications completed within target processing time
2014 2015
Jan-Jun Jul-Dec Jan-Jun
New devices 100% 100% 100%
Mean TGA processing times 119 137 122
Median TGA processing times 108 195 151
Changes or recertification 98% 100% 100%
Mean TGA processing times 86 93 77
Median TGA processing times 54 79 48

6.2 Inclusion of medical devices (including IVDs)

6.2.1 Applications

Table 27: Applications for inclusion - medical devices (including IVDs)
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Class 1 medical devicesa
Applications received 1405 1302 1201
Applications completed 1397 1303 1194
Class 1 measuring medical devices
Applications received 24 33 41
Applications completed 27 30 44
Applications on handb 7 3 4
Class 1 sterile medical devices
Applications received 108 131 118
Applications completed 115 135 130
Applications on handb 42 7 7
Class IIa medical devices
Applications received 676 679 605
Applications completed 675 742 640
Applications on handb 226 58 85
Class IIb medical devices
Applications received 350 357 411
Applications completed 339 375 385
Applications on handb 130 52 61
Class III medical devices
Applications received 219 243 182
Applications completed 262 184 188
Applications on handb 355 218 260
Class III Joint Reclassification medical devicesc
Applications received 150 114 523
Applications completed 329 231 133
Applications on handb 891 252 538
Active Implantable Medical Devices (AIMD)
Applications received 25 37 14
Applications completed 49 42 4
Applications on handb 50 23 51
Class 1 IVDs
Applications received 86 53 103
Applications completed 79 72 86
Applications on handb 8 3 7
Class 2 IVDs
Applications received 145 77 169
Applications completed 127 104 123
Applications on handb 28 5 30
Class 3 IVDs
Applications received 108 55 168
Applications completed 90 74 109
Applications on handb 34 15 22
Class 4 IVDs
Applications received 24 14 43
Applications completed 23 15 40
Applications on handb 1 0 0
  1. As Class I medical device applications are automatically included, there are no applications for this classification of device 'on hand'. Differences in the number received and finalised relate to those applications received on the last day of the reporting period.
  2. Applications on hand - figures shown are correct as of the date when the data was extracted
  3. The transition period for joint reclassification finished on 30 June 2015. A large number of applications were received at the end of this transition period, late in the January to June 2015 reporting period. As the transition period has now finished Class III joint reclassification applications will be rolled into the general Class III applications in future reports.

6.2.2 Outcomes

Class I automatically included medical devices are not counted in the outcomes for inclusion applications as these applications cannot be rejected.

Table 28: Outcomes of medical device applications by classification for January to June 2015
Number of applications
Device Classification Approved/Accepted Rejected/Lapsed Withdrawn
Class 1 1194 N/A N/A
Class 1 Measurement 36 2 6
Class 1 Sterile 124 2 4
Class IIa 595 6 39
Class IIb 362 5 18
Class III 143 36 9
Class III Reclassification 119 1 13
AIMD 3 1 0
Class 1 IVD 85 0 1
Class 2 IVD 115 0 8
Class 3 IVD 92 0 17
Class 4 IVD 38 0 2

6.2.3 Processing times

The agreed target time for level 1 application audits is 30 TGA work days and for level 2 application audits is 60 TGA work days (reflected in 'TGA days'). This does not include the period the TGA is waiting for information or payment of fees (reflected in 'sponsor days').

Table 29: Processing times for medical devices application audits (including IVDs) for January to June 2015
Number of applications Mean Audit Processing Time
Sponsor days TGA daysb
Medical devices
Applications completed without audit 1136a
Non-compulsory auditc 220 28 47
Level 1 compulsory audit 11 17 5
Level 2 compulsory audit 155 42 82
IVDs
Applications completed without audit 204a
IVD non-compulsory audit 4 36 11
IVD compulsory audit 71 22 14
  1. These figures do not include applications for Class I and Class 1 IVD auto-included devices. These applications are complete within 24 hours.
  2. TGA time starts when the application is selected for audit, and it does not include public holidays and weekends, and the time when the TGA waits for information or payment from the sponsor.
  3. Non-compulsory audit - estimate for the audit processing time does not include applications for reclassification of join replacement medical devices received during transitional period (Class III Joint Reclassification medical devices), and applications supported by EC certificates issued by certain notified bodies (for details see Increased application audit requirements for some medical devices applications).

6.3 Post-market monitoring

6.3.1 Automatically included entries

As Class I medical devices are automatically included without review by the TGA, post-market regulatory reviews are undertaken to ensure Class I are correctly included. This includes restricted word reviews, where applications for Class I devices are identified by the use of specific words indicative of risk or issues relating to the inclusion of the device, and targeted reviews that are initiated on a case by case basis (target reviews are conducted in relation to devices of any Class).

Table 30: Restricted word and targeted Class I medical devices reviews
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Restricted word reviews
Reviews completed 17 7 0
Reviews commenced 17 4 0
Reviews on hand 13 0 0
Targeted reviews
Reviews completed 114 94 63
Reviews commenced 136 33 46
Reviews on hand 413 67 50

6.3.2 Post-market reviews

TGA also undertakes a range of post market reviews for devices above Class I.

Table 31: Medical device targeted reviews
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Post market reviews
Reviews commenced - number of ARTG entries 106 40 58
Reviews completed - number of ARTG entries 75 75 44
Reviews on hand - number of ARTG entries 121 87 96

6.3.3 Medical device incident reports

Processing time is defined as the number of working days from the receipt of the notification until the incident has been investigated and resolved. Under the Therapeutic Goods Regulations 1990, working days exclude public holidays and weekends.

The target timeframe for processing of medical device incident reports is 90 working days.

Table 32: Number of medical device incident reports and processing times
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Reports received 1498 1662 1575
Reports completed 1578 2641 1499
Reports still in progress 498 169 155
Processing time
Mean TGA processing time 59 19 14
Percentage processed within target timeframe 82% 86% 85%
Table 33: Medical device incident report outcomesa
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Reviewed and used for trend analysis purposes 862 1801 1248
Reviewed, no further action required 583 689 392
Product recall 42 23 39
Recall for product correction 18 5 13
Hazard alert 36 40 20
Product notification 0 1 0
Safety alert 46 11 8
Product enhancement/improvement notice 1 1 1
Instructions for use amended 26 15 11
Referral for post-market review 2 53 22
Referral to TGA Office of Manufacturing Quality 9 1 0
Refer to another TGA Office 35 28 27
Company warned 3 0 2
Product suspended from ARTG 0 0 0
Product cancelled from ARTG 1 1 5
Manufacturing process improvements 42 11 19
Quality system process improvements 5 8 3
Maintenance carried out by the hospital 1 0 0
Change to design 6 11 3
Not device related 9 6 1
Other 97 119 44
  1. Outcomes are not mutually exclusive

Footnote

  1. Exemptions include custom made medical devices, importation of samples, etc.

7. Exports

Processing time is defined as the number of working days from the acceptance of the application including payment until formal notification of decision. Under the Therapeutic Goods Regulations 1990, working days exclude public holidays and weekends. Processing time excludes time where the TGA was unable to progress the application until the sponsor provided additional information unless otherwise specified.

7.1 Export only medicines

The target timeframe for processing of export only medicine applications and variations is 31 working days.

Table 34: Mean approval times for export only medicines
2014 2015
Jan-Jun Jul-Dec Jan-Jun
New applications
Mean TGA processing time 24 20 21
Percentage processed within target processing time 98% 100% 100%
Variations
Mean TGA processing time 22 12 13
Percentage processed within target processing time 98% 100% 98%
Table 35: Applications for new and variations to export only medicines
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Applications received 113 112 102
Applications awaiting response from sponsor 0 6 17
Applications completed
Approved N/Aa N/Aa 100
Withdrawn N/Aa N/Aa 2
Total completed N/Aa N/Aa 102
  1. N/A - This data is not available as it was not being collected for these periods.

7.2 Export certifications for medicines

The target processing time for applications for an export certificate for a medicine is 15 working days. We aim to have 100% of applications processed within the target timeframe.

Table 36: Export certification applications and mean processing times
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Applications received 1078 1146 1044
Applications completed
Approved 1093 1155 1024
Withdrawn 0 0 4
Total completed 1093 1155 1028
Processing times
Mean TGA processing time 12 12 13
Percentage processed within target time 98% 99% 97%

7.3 Export certification assessment for medical devices

The target processing time for applications for an export certificate for a medical device is 5 working days. We aim to have at least 90% of applications processed within the target timeframe.

Table 37: Medical device applications and mean processing times for export certification assessments
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Applications received 222 239 341
Applications completed
Export certificates issued 198 255 327
Applications withdrawn 0 8 5
Total completed 198 263 332
Processing time
Mean TGA processing time 3 3 3
Percentage processed within target time 98% 95% 95%

7.4 Blood permits for export

The TGA issues permits to export human blood and its fractions (products derived from human blood) on receiving written applications from medical professionals, hospitals and bone banks. Most often these professionals or health organisations approach the Australian Red Cross who then applies for the permit on their behalf. Very rarely an individual citizen may also apply with reference to his/her requirement, for example, a patient travelling overseas with Biostate injections, which is a blood fraction and requires a permit for taking it out of Australia.

In addition to issuing individual permits, the TGA also issues annual permits. Applications for these permits are submitted by commercial (pharmaceutical companies) or government organisations (such as the Australian Defence Force). The permits cover one year's worth of anticipated export supplies for these organisations.

Figure 5: Number of blood permits processed

Number of permits processed for individual permits, blood fractions and annual permits for the periods: Jan-Jun 2014; Jul-Dec 2014 and Jan-Jun 2015.

Text version of figure 5
  • Jan-Jun 2014
    • Individual permits - 50
    • Blood fractions - 45
    • Annual permits - 27
  • Jul-Dec 2014
    • Individual permits - 27
    • Blood fractions - 60
    • Annual permits - 4
  • Jan-Jun 2015
    • Individual permits - 39
    • Blood fractions - 74
    • Annual permits - 14

8. Access to unapproved therapeutic goods

8.1 Special access scheme

The Special Access Scheme (SAS) provides for the import and/or supply of an unapproved therapeutic good for a single patient, on a case by case basis. Patients are grouped into two categories under the scheme:

  • Category A: persons who are seriously ill with a condition from which death is reasonably likely to occur within a matter of months, or from which premature death is reasonably likely to occur in the absence of early treatment. In this case prescribers are required to notify the TGA of the use.
  • Category B: all other patients. In this case prescribers are required to apply to the TGA for the use.
Table 38: SAS medicines notifications and applications
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Category A notifications
Total Category A notifications 17 648 18 698 19 162
Category B applications
Approved 9 675 10 338 10 869
Cancelled 181 172 328
Rejected 22 47 14
Pending at end of reporting period 32 74 43
Total Category B applications 9 910 10 631 11 254
Table 39: SAS devices notifications and applications
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Category A notifications
Total Category A notifications 1139 1968 1488
Category B applications
Approved 1159 1121 950
Cancelled 11 75 100
Rejected 16 17 10
Pending at end of reporting period 65 5 17
Total Category B applications 1251 1218 1077
Table 40: SAS biologicals notifications and applications
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Category A notifications
Total Category A notifications 24 38 77
Category B applications
Approved 1135 1225 1217
Cancelled 0 0 0
Rejected 4 1 0
Pending at end of reporting period 23 0 22
Total Category B applications 1162 1226 1239

8.2 Clinical trials

Clinical trial notifications provide access to unapproved therapeutic goods where patients are participating in a clinical trial. Notifications are based on trial sites; however an application can be made to extend the trial to other locations. Unapproved therapeutic goods can include biologicals, devices or medicines or a combination of any of the three types of goods.

Table 41: New trial notifications that include unapproved therapeutic goods received by State or Territory (single and multi-site trials)
NSW Vic Qld SA WA Tas ACT NT Total
2014 Jan-Jun Medicine 123 92 26 25 11 1 0 0 278
Device 30 18 4 0 4 0 0 0 56
Biological 1 1 1 0 0 0 0 0 3
Medicine and device 72 19 8 7 4 0 0 0 110
Device and biological 0 0 1 0 0 0 0 0 1
Medicine and biological 0 1 0 0 0 0 0 0 1
Jul-Dec Medicine 97 95 47 20 14 3 2 0 278
Device 35 18 4 3 10 0 0 0 70
Biological 1 2 2 0 2 0 0 0 7
Medicine and device 113 32 3 11 3 0 0 0 162
Device and biological 0 0 1 0 0 0 0 0 1
Medicine and biological 0 0 0 0 0 0 0 0 0
2015 Jan-Jun Medicine 49 91 29 26 25 6 2 0 228
Device 19 25 3 10 11 1 1 0 70
Biological 0 0 1 0 0 0 0 0 1
Medicine and device 42 62 33 21 20 3 4 0 185
Device and biological 0 0 0 0 0 0 0 0 0
Medicine and biological 0 0 0 0 0 0 0 0 0
Table 42: New trial notifications that include unapproved therapeutic goods by phase (total number of trial sites notified)
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Clinical trial type

Phase 1

68

83

77

Phase 2

130

124

143

Phase 3

153

198

170

Phase 4

32

34

37

Bioavailability/equivalence

2

3

2

None specified

64

76

70

Total 449 518 499
Table 43: All notifications (includes new trials and new sites for existing trials) that include unapproved therapeutic goods, received by State or Territory (single and multi-site trial sites notified)
NSW Vic Qld SA WA Tas ACT NT Total
2014 Jan-Jun Medicine 601 400 86 52 22 5 1 0 1167
Device 93 41 4 0 4 0 0 0 142
Biological 6 1 0 0 0 0 0 0 7
Medicine and device 376 81 49 31 5 3 0 0 545
Device and biological 0 0 1 0 0 0 0 0 1
Medicine and biological 0 0 0 0 0 0 0 0 0
Jul-Dec Medicine 297 285 209 102 76 14 14 5 1002
Device 36 41 11 15 13 0 1 0 117
Biological 1 3 4 0 2 2 0 0 12
Medicine and device 191 252 140 102 62 11 9 1 768
Device and biological 1 0 0 0 0 0 0 0 1
Medicine and biological 0 0 0 0 0 0 0 0 0
2015 Jan-Jun Medicine 234 296 173 91 101 20 9 1 925
Device 32 46 9 14 16 1 1 0 119
Biological 0 0 2 0 0 0 0 0 2
Medicine and device 252 300 208 121 100 21 7 1 1010
Device and biological 0 0 0 0 0 0 0 0 0
Medicine and biological 0 0 0 0 0 0 0 0 0
Table 44: All notifications: This includes new trials and new sites for existing trials that include unapproved therapeutic goods received by phase (total number of trial sites notified).
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Clinical trial type

Phase 1

94

131

131

Phase 2

421

436

583

Phase 3

978

1088

1184

Phase 4

210

116

154

Bioavailability/equivalence

5

4

2

None specified

154

125

136

Total 1862 1900 2190

8.3 Authorised prescribers

Table 45: Authorised prescriber approvals for medicines and medical devices
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Number of approvals for medicines 213 324 356
Number of approvals for medical devices 88 129 144

Licencing and manufacturing

8.4 Manufacturing licences

Table 46: Manufacturing licence applications and status of existing licences
2014 2015
Jan-Jun Jul-Dec Jan-Jun
New licences granted 12 8 11
Withdrawn application 23 21 35
Revoked licences - voluntary 13 6 22
Revoked licences - TGA 0 0 0
Ceased 0 0 0
Suspended - Voluntary 1 0 0
Suspended - TGA 0 0 0

As at 30 June 2015, there were 404 Australian companies holding manufacturing licences covering 448 sites.

Table 47: Manufacturing licence application outcomes
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Inspections conducted 78 102 96
Satisfactory compliance 89% 97% 89%
Marginal compliance 10% 3% 11%
Unacceptable 1% 0% 0%
Processing time
Initial inspections conducted within 3 months of application 87% 88% 100%
Re-inspections conducted within 6 months of due date 64% 67% 64%

Applicants often submit applications for Good Manufacturing Practice (GMP) licences before completing all of their systems and processes. It is therefore common for initial applications to be conducted later than the target of 3 months.

8.5 Manufacturing certifications

Table 48: Manufacturing certification application by status
2014 2015
Jan-Jun Jul-Dec Jan-Jun
New applications received 69 38 56
Re-inspection applications 87 83 69
Applications completed
Certified 77 67 48
Rejected 0 39 98
Total completed 77 106 146

As at 30 June 2015, there were 419 overseas manufacturers covering 446 manufacturing sites.

Table 49: Manufacturing certification outcomes
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Inspections conducted 53 47 86
Satisfactory compliance 83% 86% 94%
Marginal compliance 17% 11% 4%
Unacceptable 0% 3% 2%
Processing time
Initial certifications inspections conducted within 6 months of application 68% 90% 84%
Certification re-inspections conducted within 6 months of due date 51% 81% 80%

Applicants often submit applications for GMP certification before completing all of their systems and processes. It is therefore common for initial applications to be conducted later than the target of 6 months.

8.6 Good Manufacturing Practice (GMP) clearances

GMP clearance is required for all medicines (unless exempt) supplied in Australia. This includes products supplied to sponsors by overseas manufacturers.

Table 50: GMP clearance application status
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Applications received 1875 1998 2050
Renewal applications 420 684 1141
Applications completed
Approved 3539 1897 2550
Rejected 73 224 91
Total completed 3612 2123 2641

9. Recalls

9.1 Medicine recalls

Table 51: Medicine recalls by reason for recall
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Adverse reactions 1 0 2
Foreign matter 0 3 3
Illegal supply 0 0 0
Impurity and degradation 3 3 4
Labelling and packaging 5 8 5
Micro-organisms 0 0 2
pH 0 0 2
Potency 1 1 1
Sterility 1 1 1
Othera 9 6 3
Total 20 22 23
  1. 'Other' includes dissolution, physical defects, observed differences, variable content, diagnostic inaccuracy and wrong product.

9.2 Medical device recalls

Table 52: Medical device (including IVDs) recalls by reason for recall
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Adverse incidents 0 1 3
Diagnostic inaccuracy 29 38 33
Electrical defect 17 25 16
Illegal supply 0 0 1
Labelling and packaging 61 43 56
Mechanical and physical defects 100 96 97
Software defects 69 59 55
Sterility 2 5 4
Othera 9 24 21
Total 287 291 286
  1. Other includes bioavailability, disintegration/dissolution, microbial contamination, variable content, foreign matter, impurity, wrong product, therapeutic inefficiency and observed differences.

9.3 Biologicals recalls

Table 53: Biologicals recalls
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Recalls to hospital level 2 0 0

10. Laboratory testing

The Laboratories Branch conducts post-market monitoring and compliance testing, investigations and reviews, as well as market authorisation assessment of therapeutic goods.

Information on the Laboratories Branch activities and Laboratory Testing Plan can be found on the TGA website.

Table 54: Samples and products tested by type of therapeutic good and percentage which failed
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Prescription medicines Total 540 377 483
% fail 1% 1% 0.2%

OTC medicines

Total 15 20 24
% fail 0% 40% 21%

Complementary medicines

Total 200 77 79
% fail 27% 30% 13%

Medical devices

Total 69 75 42
% fail 30% 19% 7%

Contracta

Total 47 23 60
% fail 0% 22% 3%

Unregisteredb

Total 186 166 111
% fail 82% 54% 84%
Total samples per half yearc 1289 1013 980
Total samples per half year
(excluding AHQ samples)
1057 738 799
Percentage fail per half year 22% 19.6% 14.3%
Total number of products tested per half yeard 507 403 405
  1. Performed on request for overseas regulators or aid agencies and encompasses medicines and medical devices.
  2. Unregistered refers to products that meet the definition of therapeutic goods but are not included on the ARTG or otherwise specifically exempted from this requirement in the legislation. This often includes adulterated complementary medicines or counterfeit products.
  3. Includes accreditation, harmonisation and quality control (AHQ) samples.
  4. The TGA may test a number of samples of each product per reporting period.
Table 55: Samples that failed laboratory testing by reason for failed between January and June 2015
Medical devices OTC medicines Prescription medicines Unregistered products Complementary medicines Total
Contamination 0 0 0 3 7 10
Formulation 0 2 1 86 1 90
Label and packaging deficiencies 0 0 0 0 1 1
Performance 2 0 0 4 1 7
Physical or mechanical properties 1 3 0 0 0 4
Total 3 5 1 93 10 112
Table 56: Batch release and export certification
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Batch releasea 225 152 242
Export certification 36 5 9
  1. Vaccines, biotechnology and blood products: evaluation of batch release documentation.
Table 57: Target timeframes in working days for laboratory testing by priority and testing type
Priority of testing Biochemical/chemical testing Microbiological testing Medical device testing
Urgent 20 (95% of target times to be met) 40 (95% of target times to be met) 20 (95% of target times to be met)
Priority 40 (80% of target times to be met) 50 (80% of target times to be met) 40 (80% of target times to be met)
Routine 50 50 50

Compliance against these timeframes are outlined in table 58.

Samples involving complex biological assays are excluded from the target turnaround timeframes.

Table 58: Compliance with testing timeframes between January and June 2015
Priority Total Percentage
Medical devices Routine 64 56%
Priority 6 100%
Urgent 1 100%
OTC medicines Routine 26 96%
Priority 0 N/A
Urgent 0 N/A
Prescription medicines Routine 125 70%
Priority 3 100%
Urgent 31 94%
Complementary medicines Routine 87 81%
Priority 3 67%
Urgent 2 100%
Unregistered products Routine 2 0%
Priority 78 94%
Urgent 24 100%

Low numbers of samples within categories may affect compliance percentages. Urgent testing may impact on the timeframes for priority and routine testing.

11. Regulatory compliance

Using signals from numerous sources as intelligence, the TGA Regulatory Compliance Unit conducts compliance and enforcement activities against a risk based compliance framework. Using principles of responsive regulation, a range of tools are used including encouragement and guidance to comply, restrictions or warnings, suspensions or sanctions and cancellations. At the apex, activities including investigations into illegal import or manufacture of unapproved and counterfeit therapeutic goods can result in criminal or civil court action. All compliance activities have the intended purpose to protect public health.

Table 59: Regulatory compliance investigations by final action taken
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Investigation in progress 257 168 73
Completed investigations
Warned 371 291 398
No offence detected 100 82 59
Goods released under Personal Import Scheme 33 29 45
Referred to another agency or department outside Health 8 5 4
Referred to another branch within the TGA 8 1 3
Import treated as abandoned goods by Customs 0 0 0
Recall of goods 2 0 0
Matters referred to the Commonwealth Director of Public Prosecutions 3 0 1
Total completed 525 408 510
Table 60: Types of products investigated
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Complementary medicines 421 260 226
Prescription medicines 318 383 477
Medical devices 100 81 75
Homoeopathic medicines 1 2 2
OTC medicines 9 32 54
Biological products 0 5 25
Other 18 14 17
Total 867 777 876
Table 61: Regulatory compliance investigations by special interest categories
2014 2015
Jan-Jun Jul-Dec Jan-Jun
Unapproved product 678 677 727
Counterfeit product 172 92 140
Parallel import/export 2 0 1
Manufacture without licence 1 0 0
Advertising offence 0 1 2
Traditional Chinese medicines 0 1 0
Other1 6 2 2
Total 859 773 872
  1. Products that fall outside the remit of the Therapeutic Goods Act 1989, for example Food products
Table 62: Investigations by complainant type and state/territory for January to June 2015
Origin ACT NSW NT QLD SA VIC WA Othera Total
Complaints resolution 3 8 0 1 0 0 0 0 12
Customs 1 200 5 64 4 105 42 2 423
External agency 5 11 0 5 1 1 0 0 23
General public 0 12 1 10 1 10 1 68 103
Patient/ practitioner 0 0 0 0 0 0 0 1 1
Sponsor/client 0 0 0 0 0 1 0 3 4
TGA internal 25 0 0 0 0 0 0 0 25
Total 34 231 6 80 6 117 43 74 591
  1. Other includes investigations of reports from Tasmania and anonymous (unknown) origin.